José Baselga

José Baselga
Nationality Spanish
Alma mater
Scientific career
Fields Oncology
Institutions

José Baselga is a Spanish medical oncologist and researcher focused on the development of novel molecular targeted agents, with a special emphasis in breast cancer. Baselga served as Physician-in-Chief at the Memorial Sloan Kettering Cancer Center until his resignation in September 2018 after it was reported that he had failed to disclose millions of dollars in financial ties with pharmaceutical companies in his research.[1][2][3][4]

Education and career

Baselga received his MD and PhD degrees from the Autonomous University of Barcelona in 1982. He completed a fellowship in Medical Oncology at Memorial Sloan-Kettering Cancer Center in New York, and subsequently stayed on as a faculty member of the Breast Medicine Service at Memorial Sloan-Kettering.

From 1996 to 2010, Baselga was the Chairman of the Medical Oncology Service and Founding Director of the recently established Vall d’Hebron Institute of Oncology (VHIO) at the Vall d'Hebron University Hospital in Barcelona. From 2010 to 2012, he was the chief of the Division of Hematology/Oncology and associate director of the MGH Cancer Center in Massachusetts.[5]

He is one of the principal investigators of the Stand Up to Cancer "Dream Team" for "Targeting the PI3K Pathway in Women’s Cancers".[6] He has been involved in the development of several targeted drugs for cancer including cetuximab, pertuzumab, trastuzumab and lapatinib.[7][8]

He was appointed Physician-in-chief at MSK in 2012[9] and was appointed a professor of medicine at Weill Cornell Medical College in 2013.[10]

According to an article in the New York Times published in September 2018, based on investigations done in cooperation with the nonprofit investigative journalism organization ProPublica, Baselga has "failed to disclose millions of dollars in payments from drug and health care companies in recent years, omitting his financial ties from dozens of research articles in prestigious publications like The New England Journal of Medicine and The Lancet".[11][12] Baselga resigned from Memorial Sloan Kettering in response to these articles.[13]

Honors and awards

  • Young Investigator Award, American Society of Clinical Oncology (ASCO) (1992-1993)[14][15]
  • Career Development Award, American Society of Clinical Oncology (ASCO) (1994-1997)[16]
  • Elected Member, American Society of Clinical Investigation (2004)[17]
  • American Italian Cancer Foundation Prize for Scientific Excellence in Medicine (2007)[18]
  • American Association for Cancer Research-Rosenthal Family Foundation Award (2008)[19]
  • King Jaime I Award in Medical Research, Valencia, Spain (2008)[20]
  • Gold Medal, Queen Sofia Spanish Institute, NY (2010)[21]
  • Joseph B. Martin Award, Massachusetts General Hospital, Boston, MA (2012)[22]
  • Elected Member, National Academy of Medicine (2014)[23]
  • John Wayne Clinical Research Lecture Award, Society of Surgical Oncology (2016)[24]
  • XXVIII Catalonia International Prize (2016)[25]
  • European Society for Medical Oncology Lifetime Achievement Award (2017)[26]

See also

References

  1. ↑ "Memorial Sloan Kettering Announces Appointment of New Physician-in-Chief". On Cancer. Memorial Sloan Kettering Cancer Center. September 5, 2012. Retrieved December 8, 2014.
  2. ↑ "José Baselga - Memorial Sloan Kettering Cancer Center". www.mskcc.org.
  3. ↑ "The José Baselga Lab - Memorial Sloan Kettering Cancer Center". www.mskcc.org.
  4. ↑ nytimes.com 13 September 2018: Top Sloan Kettering Cancer Doctor Resigns After Failing to Disclose Industry Ties
  5. ↑ "José Baselgą M.D". Breastcancer.org. September 17, 2012.
  6. ↑ "Officer Detail".
  7. ↑ "Breast Cancer Research Foundation".
  8. ↑ "José Baselga". Aura Biosciences.
  9. ↑ "Center names physician-in-chief". HemOnc Today. 10 Nov 2012.
  10. ↑ "Baselga, Jose". Weill Cornell VIVO. Retrieved 3 April 2017.
  11. ↑ Ornstein, Charles; Thomas, Katie (8 September 2018). "Top Cancer Researcher Fails to Disclose Corporate Financial Ties in Major Research Journals". The New York Times. Retrieved 10 September 2018.
  12. ↑ Thomas, Katie; Ornstein, Charles (September 9, 2018). "MSK Cancer Center Orders Staff to 'Do a Better Job' of Disclosing Industry Ties". The New York Times.
  13. ↑ "Top Breast Cancer Researcher Didn't Disclose Financial Ties". The Scientist Magazine®. Retrieved 14 September 2018.
  14. ↑ King, Jennifer C.; Lawrence, Theodore S.; Murphy, Sharon B.; Davidson, Nancy E.; Mayer, Robert J. (20 March 2010). "The American Society of Clinical Oncology Cancer Foundation Grants Program: A 25-Year Report and a Look Toward the Future". Journal of Clinical Oncology. 28 (9): 1616–1621. doi:10.1200/JCO.2009.27.4621. PMID 20177012.
  15. ↑ "Grant & Award Recipients". Conquer Cancer Foundation. 15 May 2015. Retrieved 23 January 2018.
  16. ↑ "Grant & Award Recipients". Conquer Cancer Foundation. 15 May 2015. Retrieved 23 January 2018.
  17. ↑ "ASCI - The American Society for Clinical Investigation". www.the-asci.org. Retrieved 21 December 2016.
  18. ↑ "Scientific Prize". American-Italian Cancer Foundation. Retrieved 23 January 2018.
  19. ↑ "AACR Awards". Oncology Times. 30 (10): 50. May 2008. doi:10.1097/01.COT.0000320584.98431.fa.
  20. ↑ "Histórico Premiados Investigación Médica fprj". www.fprj.es (in Spanish). Retrieved 23 January 2018.
  21. ↑ "Gold Medal Gala". spanishinstitute.org. Retrieved 6 April 2017.
  22. ↑ "Martin Prize Recipients". ecor.mgh.harvard.edu. Retrieved 23 January 2018.
  23. ↑ "José Baselga, M.D., Ph.D". National Academy of Medicine. Retrieved 21 December 2016.
  24. ↑ "John Wayne Clinical Research Lecturers". www.surgonc.org. Retrieved 23 January 2018.
  25. ↑ "Previous winners". Generalitat de Catalunya. Retrieved 23 January 2018.
  26. ↑ "ESMO Lifetime Achievement Award | Oncology Awards | ESMO". www.esmo.org. Retrieved 23 January 2018.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.